Typically the drug substance attribute (assay) is used in formulating the batch during manufacture.
Genotyping results were consistent among laboratories, with most differences in allele assignments attributed to assay design and variability in reported allele nomenclature, particularly for CYP2D6, UGT1A1, and VKORC1.
Due to their high-throughput and versatile attributes, these assays provide invaluable tools for probing and perturbing protein membrane binding interactions.
Our results, and those of other researchers that imply the absence of a trade-off, could be attributed to assay conditions in which food is not a limiting resource [ 47].
The obtained results show that there is no significant change on appearance and physical attributes, also the assay and impurity results show the maximum 3.4 % decrease in the assay from initial potency.
The assay attributes include limit of detection, reproducibility/reliability, inter-laboratory variation, specificity, time, and cost.
The investigated quality and performance attributes include drug assay, content uniformity, API particle size in ointment, rheological characteristics, in vitro drug release and in vitro transcorneal drug permeation.
The ability of this technique to reveal single vesicle formation with high spatial and temporal resolution is likely due to three main attributes of this assay.
The particular attributes of our assay have allowed us to demonstrate that retromutagenesis can be a significant cause of mutation in certain circumstances.
The analytical attributes of the assay include a relative insensitivity to extrinsic LPS contamination, whole blood sample requirement (no need for centrifugation), rapid time to final result (approximately 30 minutes) with a relatively wide dynamic range (25 to 2,500 pg/ml WHO LPS) and a unit dose format that allows individual patient assays, obviating the need for sample batching.
